Quest Diagnostics Stock Surges on Strong Q2 Earnings and Raised Outlook

Shares of Quest Diagnostics (NYSE: DGX) surged in pre-market trading Tuesday after the diagnostics company reported second-quarter earnings and revenue that surpassed Wall Street estimates and raised its full-year financial guidance.

Strong Quarterly Performance

Quest Diagnostics announced second-quarter adjusted earnings per share (EPS) of $3.12, significantly exceeding the analyst consensus of $2.82. Quarterly revenue came in at $3.04 billion, ahead of the $2.97 billion forecast and representing a 10.2% increase year-over-year. The results, released before the market opened, extended the company's track record of beating bottom-line estimates for a fourth consecutive quarter.

Following the strong results, the company provided an optimistic forecast for the remainder of the year. Quest lifted its full-year 2026 guidance, now targeting:

• Revenue in the range of $11.95 billion to $12.05 billion
• Adjusted EPS between $11.05 and $11.25

Ad

Both of these updated ranges are above prior consensus estimates, signaling management's confidence in sustained business momentum.

Market Reaction and Analyst View

Investors responded positively, driving the stock up 7.3% in pre-open trading to $225.09. This price action established a new 52-week high, surpassing the previous peak of $219.20. The rally was particularly notable as it occurred against a challenging market backdrop, with the S&P 500, Dow Jones Industrial Average, and Nasdaq all trading lower.

Analyst confidence also provided a tailwind for the shares. Following the report, Jefferies raised its price target on Quest Diagnostics to $225 from $220, while maintaining a Buy rating. The firm cited the beat on both sales and earnings as justification for the higher valuation. The combination of a significant earnings surprise, an upgraded outlook, and supportive analyst action created a strong catalyst for the stock.